Teh, Charis E.
Gong, Jia-Nan
Segal, David
Tan, Tania
Vandenberg, Cassandra J.
Fedele, Pasquale L.
Low, Michael S. Y.
Grigoriadis, George
Harrison, Simon J.
Strasser, Andreas
Roberts, Andrew W. http://orcid.org/0000-0002-7341-5720
Huang, David C. S. http://orcid.org/0000-0002-3101-4873
Nolan, Garry P.
Gray, Daniel H. D. http://orcid.org/0000-0002-8457-8242
Ko, Melissa E.
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1089072, 1016701, 1020363, 1113577, 1016701, 1079560)
Australian-American Fulbright Commission (NA)
U.S. Department of Defense (NA)
Northrop Grumman (NA)
Article History
Received: 29 March 2019
Revised: 13 January 2020
Accepted: 14 January 2020
First Online: 27 January 2020
Compliance with ethical standards
:
: GPN is a paid consultant for Fluidigm, the manufacturer that produced some of the reagents and instrumentation used in this study. CET, JG, DS, TT, CJV, PLF, MSYL, AS, AWR, DCSH, and DHDG are employees of Walter and Eliza Hall Institute of Medical Research which receives milestone and royalty payments related to venetoclax (iBCL-2). SJH has received research funding and has participated in Advisory boards from Janssen Cilag (bortezomib), Abbvie (venetoclax), and Amgen (iMCL-1). Researchers at the Walter and Eliza Hall Institute of Medical Research in the Strasser, Roberts, Huang, and Gray laboratories collaborate with Servier on the development of MCL-1 inhibitors. All other authors declare no competing financial interests.